An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Biomea Fusion, Inc. granted 8 new employees non-qualified stock options to purchase 80,250 shares of common stock. The options will vest quarterly over four years, contingent on continued employment. These awards were made under the 2023 Inducement Equity Plan to attract new talent, in compliance with Nasdaq rules.
Biomea Fusion, Inc. ha concesso a 8 nuovi dipendenti opzioni su azioni non qualificate per l'acquisto di 80.250 azioni ordinarie. Le opzioni matureranno trimestralmente nel corso di quattro anni, a condizione che il rapporto di lavoro continui. Questi premi sono stati assegnati nell'ambito del Piano di Equità di Induzione 2023 per attrarre nuovo talento, in conformità con le regole del Nasdaq.
Biomea Fusion, Inc. otorgó a 8 nuevos empleados opciones sobre acciones no calificadas para comprar 80.250 acciones comunes. Las opciones se acumularán trimestralmente durante cuatro años, sujeto a la continuidad del empleo. Estos premios se realizaron bajo el Plan de Acciones de Inducción 2023 para atraer nuevo talento, conforme a las normas de Nasdaq.
Biomea Fusion, Inc.는 8명의 신입 직원들에게 80,250주의 보통주를 매입할 수 있는 비자격 주식 옵션을 부여했습니다. 옵션은 4년간 분기별로 획득되며, 계속된 고용이 조건입니다. 이러한 수여는 2023년 유인 자본 계획에 따라 새로운 인재를 유치하기 위해 수행되었으며, 나스닥 규정을 준수합니다.
Biomea Fusion, Inc. a accordé à 8 nouveaux employés des options d'achat d'actions non qualifiées pour acquérir 80 250 actions ordinaires. Les options seront acquises par trimestre sur quatre ans, sous réserve d'un emploi continu. Ces attributions ont été faites dans le cadre du Plan d'Equité d'Incitation 2023 pour attirer de nouveaux talents, conformément aux règles du Nasdaq.
Biomea Fusion, Inc. gewährte 8 neuen Mitarbeitern nicht qualifizierte Aktienoptionen für den Erwerb von 80.250 Stammaktien. Die Optionen werden vierteljährlich über vier Jahre hinweg vesten, vorausgesetzt, das Beschäftigungsverhältnis besteht weiterhin. Diese Auszeichnungen wurden im Rahmen des Anreizaktienplans 2023 verliehen, um neues Talent anzuziehen, in Übereinstimmung mit den Nasdaq-Regeln.
Positive
None.
Negative
None.
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases, today announced that on May 1, 2024, the compensation committee of Biomea’s board of directors granted 8 new employees non-qualified stock options to purchase an aggregate of 80,250 shares of the Company’s common stock. The shares underlying each employee’s stock options will vest 1/16 on a quarterly basis over four years, in each case subject to each such employee’s continued employment with the Company on such vesting dates. All of the above-described awards were made under Biomea’s 2023 Inducement Equity Plan (the “Plan”).
The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by Biomea’s board of directors on November 17, 2023.
About Biomea Fusion
Biomea Fusion is a clinical stage biopharmaceutical company focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response.
We are utilizing our proprietary FUSION™ System to discover, design and develop a pipeline of next-generation covalent-binding small molecule medicines designed to maximize clinical benefit for patients with various cancers and metabolic diseases, including diabetes. We aim to have an outsized impact on the treatment of disease for the patients we serve. We aim to cure.
How many employees were granted stock options by Biomea Fusion, Inc.?
Biomea Fusion, Inc. granted stock options to 8 new employees.
How many shares of common stock can be purchased through the stock options?
A total of 80,250 shares of the Company’s common stock can be purchased through the stock options.
What is the vesting schedule for the stock options?
The shares underlying each employee’s stock options will vest 1/16 on a quarterly basis over four years.
When was the Plan under which the awards were granted adopted by Biomea’s board of directors?
The Plan under which the awards were granted was adopted by Biomea’s board of directors on November 17, 2023.
Why were the awards granted to the employees?
The awards were granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
biomea fusion, llc was formed in 2017 by a small group of biotech executives. we are dedicated to developing innovative medicines for patients. it is our goal to design and clinically develop patient friendly therapies with higher efficacy than the current standard of care. the more precise a therapeutic agent is, the better the potential outcomes for individual patients’ needs. we are a precision oncology company developing novel small molecules that target aggressive forms of cancer. patients with these aggressive tumors typically exhibit high mortality rates and suffer from inadequate treatment options. with our current program, we are targeting specific changes to the dna of patients, which can be isolated as key drivers for tumor growth. we leverage our internal expertise and compliment it with computational drug design technology to build novel medicines for the future. we have significantly invested in the upfront development of our targeted therapies and are conducting bro
